Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAbbott Medical Devices

About this trial

The objective of this clinical investigation is to evaluate the feasibility, safety, and effectiveness of a concomitant procedure involving the Volt PFA System and Amulet 2 device in patients indicated for both AF ablation and percutaneous LAAO.

Eligibility criteria

Qualifiers

Subject must provide written informed consent prior to any clinical investigation-related procedure.

18 years of age or older, or the age of legal consent

CHA2DS2-VASc score of ≥ 3 for women and ≥ 2 for men

Able to stop anticoagulation by 90 days post index procedure

Disqualifiers

Known contraindication or allergy to NOACs or aspirin, preventing use of the drugs post-procedure

Required to take P2Y12 platelet inhibitor after the study procedure (e.g., due to percutaneous coronary intervention)

Patients with heart prosthetic valves

Patient implanted with an inferior vena cava filter

Trial design

Treatments tested in this trial

  • PVI Ablation
  • Left Atrial Appendage Occluder Implant

Treatment groups

240 Participants
are divided into 1 treatment group

Sponsors and collaborators